CTLA4 and uveal melanoma: ICIs, including anti-CTLA-4 and anti-PD-1 agents, aim to overcome this evasion by reinvigorating exhausted T cells and have shown improved survival in metastatic uveal melanoma patients, albeit with notable immune-related adverse events such as non-infectious uveitis.28